Allstate
ALL
$216.59
-0.31%
The Allstate Corporation is a major US property and casualty (P&C) insurer, with its core business centered on personal auto insurance, complemented by homeowners insurance and other protection products. The company operates as a traditional industry leader, distributing its products primarily through a network of exclusive agents. The current investor narrative is dominated by the company's recovery from prior underwriting challenges, with recent financial results showing a significant rebound in profitability, as evidenced by strong quarterly earnings, which is driving a reassessment of its earnings power and capital return potential in a stabilizing insurance market.…
ALL
Allstate
$216.59
Related headlines
Investment Opinion: Should I buy ALL Today?
Rating & Thesis: Hold. Allstate presents a classic 'show me' story where the valuation is compelling but the sustainability of its dramatic earnings rebound is unproven, warranting a cautious stance despite the bullish momentum. The mixed analyst sentiment, with recent downgrades offsetting outperform ratings, supports this neutral view.
Supporting Evidence: The valuation is undeniably cheap, with a trailing P/E of 5.29x and forward P/E of 8.25x, both deeply discounted versus industry peers. Profitability metrics have soared, with Q4 net margin at 23.1% and ROE at 33.6%. The company generates enormous cash flow ($9.88B TTM FCF) and maintains a fortress balance sheet (D/E 0.24). However, revenue growth remains anemic at 1.52% YoY, and the stock has chronically underperformed the broader market over the past year.
Risks & Conditions: The thesis would upgrade to a Buy if the company demonstrates margin sustainability over the next two quarters (e.g., net margin holding above 15%) or announces a material increase in capital returns. It would downgrade to a Sell if quarterly net income falls below $2B or if the forward P/E expands above 12x without corresponding earnings growth. Relative to its history and the current evidence, the stock appears fairly valued—the deep P/E discount appropriately prices in the risk of earnings mean reversion.
Sign up to view all
ALL 12-Month Price Forecast
The investment case is bifurcated: the valuation is profoundly cheap, but it cheap for a reason—the market doubts the durability of Allstate's earnings renaissance. The base case of moderated but still-strong profitability and range-bound trading is most probable. The stance would upgrade to bullish on evidence of margin sustainability (two consecutive quarters of net margin >18%) or a transformative capital return event. It would turn bearish if quarterly earnings fall back to 2024 levels, proving the recovery was fleeting.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $281.57 and implied upside of +30.0% versus the current price.
Average Target
$281.57
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$173 - $282
Analyst target range
Analyst coverage for this large-cap stock appears limited in the provided data, with only 3 analysts cited for estimates, which is unusually low and may indicate a subset of data. The consensus sentiment, based on recent institutional ratings, is mixed but leans positive, with firms like Mizuho and Keefe, Bruyette & Woods maintaining 'Outperform' ratings, while Wells Fargo and Citigroup have 'Equal Weight' and 'Neutral' stances, respectively. The target price range implied by revenue and EPS estimates is wide, with estimated EPS for the high case at $26.18 and the low at $24.19, reflecting differing assumptions about future underwriting results and investment income; a recent downgrade from TD Cowen from 'Buy' to 'Hold' introduces a note of caution, suggesting some analysts believe the strong recovery may already be priced in.
Bulls vs Bears: ALL Investment Factors
The bull case, anchored in a dramatic profitability recovery and extreme valuation discount, currently holds stronger evidence. The bear case hinges on the sustainability of peak-cycle margins and skepticism that the recovery is fully priced. The single most important tension in the investment debate is whether the Q4 2025 net margin of 23.1% represents a new, sustainable baseline of earnings power or a cyclical peak that will revert to lower historical norms. The resolution of this question will determine if the stock's deep discount is a value trap or a compelling opportunity.
Bullish
- Exceptional Profitability Rebound: Q4 2025 net income surged to $3.83B, yielding a net margin of 23.1%, up from 11.8% in the year-ago quarter. Gross margin expanded dramatically to 53.0% from 30.1%, demonstrating highly successful pricing and claims management actions.
- The stock trades at a trailing P/E of 5.29x and a forward P/E of 8.25x, a significant discount to typical P&C industry averages in the low-to-mid teens. This suggests the market is undervaluing the company's newly demonstrated earnings power.
- Robust Cash Generation & Capital Return: Trailing twelve-month free cash flow is a massive $9.88B, providing ample liquidity for shareholder returns. The conservative debt-to-equity ratio of 0.24 and a low payout ratio of 11.2% indicate significant capacity for increased dividends and buybacks.
- Strong Technical Momentum: The stock is in a sustained uptrend, up 9.93% over the past three months with positive relative strength of 6.34 versus the market. It trades at 79% of its 52-week range ($188.08-$219.48), indicating positive momentum without being overextended.
Bearish
- Earnings Volatility & Peak Cycle Risk: The recent Q4 2025 net margin of 23.1% is exceptionally high and may not be sustainable, as evidenced by the forward P/E (8.25x) being higher than the trailing P/E (5.29x), implying expected earnings moderation. Historical quarterly net margins have swung from 2.1% to 23.1% over the past two years.
- Analyst Skepticism & Limited Coverage: Analyst coverage appears thin (only 3 cited), and sentiment is mixed with recent downgrades like TD Cowen's move from 'Buy' to 'Hold'. This suggests some on Wall Street believe the strong recovery may already be priced in at current levels.
- Modest Revenue Growth Profile: Q4 2025 revenue grew a modest 1.52% YoY to $16.59B, indicating a mature, slow-growth business. The company's core auto insurance market is highly competitive and subject to regulatory pressures, limiting top-line expansion potential.
- Chronic Market Underperformance: Despite recent strength, the stock has underperformed the S&P 500 by 21.34 percentage points over the past year. Its low beta of 0.22 implies lower volatility but also suggests it lacks the explosive upside of high-growth stocks, potentially limiting appeal in a bull market.
ALL Technical Analysis
The stock is in a sustained uptrend, evidenced by a 9.25% gain over the past year, and is currently trading at approximately 79% of its 52-week range ($188.08 to $219.48), indicating it is in the upper half of its annual band and reflecting positive momentum but not extreme overextension. Recent momentum is strong and accelerating, with the stock up 3.99% over the past month and 9.93% over the past three months, both figures outpacing the broader market as indicated by positive relative strength readings of -4.71 and 6.34, respectively, suggesting the stock is catching up after a period of underperformance. Key technical support is at the 52-week low of $188.08, while immediate resistance is at the 52-week high of $219.48; a breakout above this level would signal a continuation of the bullish trend, while the stock's low beta of 0.22 indicates it is significantly less volatile than the market, which implies lower risk for position sizing but also less explosive upside potential.
Beta
0.22
0.22x market volatility
Max Drawdown
-13.7%
Largest decline past year
52-Week Range
$188-$221
Price range past year
Annual Return
+9.8%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | +6.1% | +10.0% |
| 3m | +8.8% | +4.1% |
| 6m | +13.1% | +5.7% |
| 1y | +9.8% | +29.0% |
| ytd | +6.3% | +5.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $16.59 billion representing a 1.52% year-over-year increase, and the quarterly trend shows revenue stabilizing in the $16-$17 billion range after volatility in prior periods. Profitability has dramatically improved, with Q4 2025 net income surging to $3.83 billion, yielding a robust net margin of 23.1%, and gross margin expanded significantly to 53.0% from 30.1% in the year-ago quarter, indicating successful pricing actions and claims management. The balance sheet is healthy with a conservative debt-to-equity ratio of 0.24, and the company generates substantial cash flow, evidenced by trailing twelve-month free cash flow of $9.88 billion, which provides ample liquidity for dividends, share repurchases, and growth investments without reliance on excessive external financing.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$9.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is a very low 5.29x, while the forward PE is 8.25x; the gap suggests the market expects a moderation from the exceptionally high earnings of the most recent quarter but still anticipates strong profitability. Compared to typical industry averages for P&C insurers, which often trade in the low-to-mid teens PE range, Allstate's sub-10x multiples represent a significant discount, which may be attributed to its historical volatility in earnings or a perception of being a slower-growth, mature insurer. Historically, the stock's own trailing PE has fluctuated wildly, from negative figures during loss periods to over 30x; the current 5.29x is near the lower end of its recent positive range, suggesting the market may be undervaluing the current level of normalized earnings or pricing in a reversion to lower profitability.
PE
5.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1458x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is earnings volatility and potential reversion from peak profitability. The Q4 2025 net margin of 23.1% is a dramatic outlier compared to the 2.1% margin seen in Q2 2024, highlighting the cyclicality inherent in P&C underwriting. While the balance sheet is strong with a D/E of 0.24, the company's revenue growth is modest at 1.52% YoY, creating dependence on maintaining these elevated margins to justify any multiple expansion. A failure to sustain current underwriting discipline could lead to significant earnings disappointment.
Market & Competitive Risks: The stock trades at a significant discount to industry P/E averages, but this discount could persist or widen if the market continues to view Allstate as a low-growth, mature insurer. The core personal auto market is intensely competitive and faces potential disruption from telematics and direct-to-consumer models. Regulatory pressures on pricing and claims practices in key states present ongoing headwinds. The stock's low beta of 0.22 offers downside protection but also indicates it may not participate fully in broad market rallies.
Worst-Case Scenario: The worst-case scenario involves a rapid normalization of underwriting margins combined with a broader market downturn. If net margins revert to the ~8-10% range seen in 2024, earnings could fall by over 50% from Q4 2025 levels. This could trigger analyst downgrades and multiple compression, driving the stock back toward its 52-week low of $188.08. From the current price of $212.88, this represents a realistic downside of approximately -12%. A more severe underwriting shock or catastrophic loss event could push the stock below this level, but the strong balance sheet and cash flow provide a material cushion.
FAQ
The primary risk is earnings mean reversion: the Q4 2025 net margin of 23.1% is unlikely to be sustained, and a drop back toward historical averages would crush earnings. Competitive and regulatory risks in the core auto insurance market could pressure pricing power. Macro risks are muted due to the stock's low beta (0.22), but a severe recession could increase claims. Finally, sentiment risk exists, as the stock has chronically underperformed the market, which may continue if growth remains scarce.
The 12-month outlook presents three scenarios. The base case (55% probability) sees the stock trading between $200 and $220 as earnings moderate but remain robust. The bull case (30% probability) targets $225-$240 if margins hold and capital returns accelerate. The bear case (15% probability) sees a retest of the 52-week low near $188 if earnings disappoint. The most likely outcome is range-bound trading, with direction determined by the sustainability of profits in the coming quarters.
ALL appears significantly undervalued on a static, trailing earnings basis. A trailing P/E of 5.29x and a Price/Sales of 0.82x are far below typical Property & Casualty insurer multiples. However, this discount reflects market skepticism. The forward P/E of 8.25x, while still cheap, implies the market expects earnings to fall roughly 35% from recent highs. The valuation is thus a discount to current reality but may be fair if earnings normalize lower.
ALL is a compelling but high-conviction buy only for patient value investors. The stock trades at a deep discount (P/E of 5.29x) and generates massive cash flow, but the investment hinges on believing its recent profit surge is sustainable. With a 30% probability assigned to a bullish re-rating and a 15% chance of a bearish decline to the $188 support, the risk/reward is favorable for those who can tolerate earnings volatility. It is not a good buy for growth investors or those seeking short-term momentum.
ALL is primarily suitable for a medium- to long-term investment horizon (2+ years). The thesis of valuation normalization and earnings sustainability requires time to play out. The low beta and dividend provide stability for long-term holders. It is less suitable for short-term trading due to its lower volatility and dependence on quarterly earnings catalysts for major moves. A minimum holding period of 12-18 months is suggested to allow for the investment narrative to evolve.
